

**Louisiana Medicaid
Point-of-Sale (POS) Requirements for Agents
That are Not Subject to Prior Authorization**

Acetaminophen and Aspirin Adult Maximum Daily Dose Limit

The adult maximum daily dose of acetaminophen is 4000mg, from all submitted prescription claims for acetaminophen-containing products. The adult maximum daily dose of aspirin is 6000mg, from all submitted prescription claims for aspirin-containing products.

Beyaz® (Drospirenone/Ethinyl Estradiol/Levomefolate Calcium) Excluded Diagnosis Codes

The following acne-related ICD-10 diagnosis codes for Beyaz® (drospirenone/ethinyl estradiol/levomefolate calcium) are **not** payable: L70* and L73.0.

Carafate® (Sucralfate) Duration of Therapy Limit

Carafate® (sucralfate) is subject to a duration of therapy limit. This limit is 90 days in a calendar year. For use beyond 90 days duration, an appropriate diagnosis code is required at POS. The ICD-10 diagnosis codes listed in Table 1 are exempt from the Carafate® duration of therapy limit.

Table 1. Diagnosis Codes that are Exempt from Sucralfate (Carafate®) Duration of Therapy Limits

Abscess of Esophagus	K20.8
Barrett's Esophagus	K22.7*
Crohn's Disease	K50.*
Chronic Pancreatitis	K86.0, K86.1
Duodenal Ulcer	K26.*
Esophagitis, Unspecified	K20.9
Gastric Hyperacidity	K30
Gastric Ulcer	K25.*
Gastritis/Duodenitis	K29.*
Gastroesophageal Reflux Disease (GERD)	K21.9
Gastrointestinal Hemorrhage	K92.2
Malignant Mast Cell Tumors	C96.2*
Multiple Endocrine Adenomas	D44.0, D44.2, D44.9
Peptic Ulcer	K27.*
Reflux Esophagitis	K21.0
Ulcer of Esophagus with OR without Bleeding	K22.1*
Zollinger-Ellison Syndrome	E16.4

* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

Cuprimine®, Depen® (Penicillamine) Quantity Limit

Cuprimine® capsules and Depen® tablets (penicillamine) are limited to a quantity of 240 capsules/tablets per 30 days.

Fycompa® Age Limit

Formatted Table

Formatted: Font: Bold

Formatted: Font: Not Bold

Fycompa® (perampanel) is indicated for adult and pediatric patients 4 years of age and older. The age limit may be overridden at the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify necessity of prescribing perampanel for a child younger than 4 years of age.

Isotretinoin Capsule Prescription Requirement

Only original handwritten prescriptions signed by the prescribing practitioner, with no provision for refill, are covered.

Nexplanon® (Etonogestrel) Quantity Limit

The quantity limit for Nexplanon® (etonogestrel) is one implant every two years. The quantity limit may be overridden by the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify the necessity of exceeding the quantity limit.

Oralair® (Mixed Grass Allergen Extract) Reimbursement Requirements

The following is required for reimbursement related to the above-referenced allergen extract(s):

- Pharmacy: A pharmacy claim for an auto-injectable epinephrine product within the previous 12 months.
- Prescriber: One of the following specialties:
 - Allergy
 - Otology/Laryngology/Rhinology
 - Ophthalmology/Otology/Laryngology/Rhinology

Prudoxin®, Zonalon® (Doxepin) Age Limit, Diagnosis Required, Therapeutic Duplication, Quantity Limit

Prudoxin® and Zonalon® (doxepin) are limited to use in adults 18 years of age or older. These agents require a diagnosis code at the pharmacy POS (See Table 2). These agents are monitored at the pharmacy POS for therapeutic duplication with each other. These agents are limited to a quantity of 45 grams per 30 days.

Rybelsus® (Semaglutide) Prior Use of Metformin is Required

The pharmacy POS system verifies that there has been at least a 90-day supply of metformin in the previous 180-day period **OR** that there has been at least a 60-day supply of Rybelsus® or any other incretin mimetic/enhancer in the previous 90-day period.

Samsca® (Tolvaptan) Quantity Limit

Samsca® (tolvaptan) 30mg tablet is limited to a quantity of 60 tablets per fill. Samsca® (tolvaptan) 15mg tablet is limited to a quantity of 30 tablets per fill.

Secuado® (Asenapine) Transdermal Maximum Dose, Therapeutic Duplication, Diagnosis Required, Quantity Limit

Secuado® (asenapine) transdermal patch is limited to a maximum dose of 0mg for recipients 0-17 years of age. Secuado® is monitored at the pharmacy POS for therapeutic duplication with oral antipsychotics. Secuado® requires a diagnosis code at POS (See Table 2). All strengths are limited to a quantity of 30 patches per 30 days.

Sunosi® (Solriamfetol) and Wakix™ (Pitolisant) Age Limit, Concurrent Use Restriction, Therapeutic Duplication, Diagnosis Required

Sunosi® (solriamfetol) and Wakix™ (pitolisant) are limited to use in adults 18 years of age or older. These agents are monitored at the pharmacy POS for concurrent use with sedative-hypnotics. These agents are monitored at the pharmacy POS for therapeutic duplication with each other **OR** with any other stimulant or related agent. Sunosi® (solriamfetol) and Wakix™ (pitolisant) require a diagnosis code at POS. (See Table 2)

Formatted: Space After: 8 pt

Formatted: Font: Not Bold, No underline

Formatted: Font: 5 pt

Formatted: Space After: 0 pt

Formatted: Font: Not Bold, No underline

Tosymra® (Sumatriptan) Quantity Limit and Diagnosis Required if Younger than 18 Years Old

The quantity limit for Tosymra® is 6 units per 30 days. The quantity limit may be overridden at the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify the necessity of exceeding the quantity limit. Tosymra®, like all other triptans that are listed on the PDL/NPDL, requires a diagnosis code at POS for recipients who are younger than 18 years old. (See Table 2)

Table 2. Agents that have diagnosis code requirements (but are not subject to prior authorization)		
Medication	Diagnosis Code	Diagnosis Description
Actimmune® (Interferon gamma-1b)	D71	Chronic Granulomatous Disease
	Q78.2	Malignant Osteopetrosis
Alferon N® (Interferon alfa-N3)	A63.0	External Genital and Perianal Warts (Condylomata Acuminata)
Cialis® (Tadalafil) 2.5mg, 5mg	N40.*	Benign Prostatic Hyperplasia
Egrifta®; Egrifta SV™ (Tesamorelin)	B20	Human Immunodeficiency Virus [HIV] Disease
Exjade®, Jadenu® (Deferasirox) [2-9 years old]	E83.111	Chronic Iron Overload Due to Blood Transfusions
Exjade®, Jadenu® (Deferasirox) [10 years and older]	E83.111	Chronic Iron Overload Due to Blood Transfusions
	D56.8	Hemoglobin C/β-Thalassemia
	D56.5	Hemoglobin E/β -Thalassemia
	D57.4*	Hemoglobin S/β-Thalassemia
	D56.0	α-Thalassemia Intermedia [Hemoglobin H Disease]
	D56.1	β-Thalassemia Intermedia
Fabrazyme® (Agalsidase beta)	E75.21	Fabry (-Anderson) Disease
Flolan®, Veletri® (Epoprostenol Sodium); Remodulin® (Treprostinil Sodium) Injection	I27.0, I27.2, I27.89, P29.3	Pulmonary Arterial Hypertension (PAH)
HIV Agents	B16.1, B16.2, B16.9	Acute Hepatitis B
	B18.0, B18.1	Chronic Viral Hepatitis B
	B19.1, B19.10, B19.11	Unspecified Viral Hepatitis B
	B20	HIV
	B97.35	HIV, type 2
	W46.0XXA, W46.0XXD	Contact with Hypodermic Needle
	W46.1XXA, W46.1XXD	Contact with Contaminated Hypodermic Needle

	Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmitted
	Z20.6	Contact with and (suspected) exposure to HIV
	Z20.828, Z20.89, Z20.9	Contact with and (suspected) exposure to other or unspecified communicable diseases
	Z22.51	Carrier of Viral Hepatitis B
	Z72.5, Z72.51, Z72.52, Z72.53	High Risk Sexual Behavior
	Z77.21	Contact with and (suspected) exposure to potentially hazardous body fluid
	Z77.9	Other Contact with and (suspected) exposures hazardous to health
Intron-A® (Interferon alfa-2B Recombinant)	C46.*	AIDS-Related Kaposi's Sarcoma
	B18.0, B18.1	Chronic Hepatitis B
	B18.2	Chronic Hepatitis C
	C82.*	Follicular Lymphoma
	C91.4*	Hairy Cell Leukemia
	C43.*	Melanoma
Lumizyme® (Alglucosidase alfa)	E74.02	Pompe Disease
Onpattro® (Patisiran); Tegsedi™ (Inotersen)	E85.1	Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Proleukin® (Aldesleukin)	C43.*	Melanoma
	C64.*	Renal Cell Carcinoma
Pulmozyme® (Dornase alfa)	E84.*	Cystic Fibrosis
Radicava® (Edaravone); Rilutek®, Tiglutik® (Riluzole)	G12.21	Amyotrophic Lateral Sclerosis

Table 2. Agents that have diagnosis code requirements (but are not subject to prior authorization) continued

Medication	Diagnosis Code	Diagnosis Description
Lumizyme® (Alglucosidase alfa)	E74.02	Pompe Disease
Onpattro® (Patisiran); Tegsedi™ (Inotersen)	E85.1	Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Proleukin® (Aldesleukin)	C43.*	Melanoma
	C64.*	Renal Cell Carcinoma
Prudoxin®, Zonalon® (Doxepin)	L20*	Atopic Dermatitis
	L28.0	Lichen Simplex Chronicus
Pulmozyme® (Dornase alfa)	E84.*	Cystic Fibrosis
Radicava® (Edaravone); Rilutek®, Tiglutik® (Riluzole)	G12.21	Amyotrophic Lateral Sclerosis
Secuado® (Asenapine) Transdermal	F20*	Schizophrenia
Soliris® (Eculizumab)	D59.3	Hemolytic-Uremic Syndrome
	D59.5	Paroxysmal Nocturnal Hemoglobinuria [Marchiafava-Micheli]
	G36.0	Neuromyelitis optica spectrum disorder (NMOSD)
	G70.0	Myasthenia Gravis
Sunosi® (Solriamfetol)	G47.4*	Narcolepsy
	G47.33	Obstructive Sleep Apnea
Sylatron® (Peginterferon alfa-2b)	C43.*	Melanoma
Tosymra® (Sumatriptan) [diagnosis required for <18 Years Old]	G43.0*, G43.1*, G43.7*	Migraine With or Without Aura, Chronic Migraine Without Aura
Wakix™ (Pitolisant)	G47.4*	Narcolepsy

*Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

Formatted: Left, Indent: Left: -0.01"

Formatted Table

Formatted: Left, Indent: Left: -0.01"

Formatted: Font: Not Bold

Formatted: Left, Indent: Left: -0.01", Right: 0"

Formatted: Left, Indent: Left: -0.01"

Formatted Table

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Formatted: Indent: Left: -0.01"

References

- Accutane (isotretinoin) [package insert]. Nutley, NJ: Roche Laboratories Inc.; November 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018662s059lbl.pdf
- Actimmune (interferon gamma-1b) [package insert]. Lake Forest, IL: Horizon Pharma USA Inc.; May 2017. <https://www.hzndocs.com/ACTIMMUNE-Prescribing-Information.pdf>
- Alferon N (interferon alfa-n3) [package insert]. Philadelphia, PA: Hemispherx Biopharma; November 2019. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=241ece31-e649-021a-e054-00144ff8d46c&type=display>
- Beyaz (drospirenone/ethynyl estradiol/levomefolate calcium) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2017. https://labeling.bayerhealthcare.com/html/products/pi/fhc/Beyaz_PI.pdf
- Carafate (sucralfate) [package insert]. Madison, NJ: Allergan USA Inc.; June 2018. https://www.allergan.com/assets/pdf/carafate_pi
- Cialis (tadalafil) [package insert]. Indianapolis, IN: Lilly USA LLC; February 2018. <https://pi.lilly.com/us/cialis-pi.pdf>
- Cuprimine® (penicillamine) [package insert]. Bridgewater, NJ: Aton Pharma, Inc., a division of Valeant Pharmaceuticals North America LLC; September 2018. <https://www.bauschhealth.com/Portals/25/Pdf/PI/Cuprimine-PI.pdf>
- Depen (penicillamine) [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; January 2019. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=38f8ae60-b354-11de-8a39-0800200c9a66&type=display>
- Egrifta (tesamorelin) [package insert]. Montréal, Québec, Canada: Theratechnologies Inc.; July 2018. http://egrifta.com/PDF/Prescribing_Info_en.pdf
- Egrifta SV (tesamorelin) [package insert]. Montréal, Québec, Canada: Theratechnologies Inc.; October 2019. https://www.egriftasv.com/include/PDF/HCP/Prescribing_Info_en.pdf
- Exjade (deferasirox) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2019. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/exjade.pdf>
- Fabrazyme (agalsidase beta) [package insert]. Cambridge, MA: Genzyme Corporation; December 2018. <http://products.sanofi.us/Fabrazyme/Fabrazyme.pdf>
- Flolan (epoprostenol) [package insert]. Triangle Park, NC: GlaxoSmithKline; December 2018. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Flolan/pdf/FLOLAN-PI-PIL.PDF
- Fycompa (perampanel) [package insert]. Woodcliff Lake, NJ: Eisai R&D Management Co; May 2019. https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf?v=20190125
- Intron-A (interferon alfa-2b) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; February 2016. https://www.merck.com/product/usa/pi_circulars/i/intron_a/intron_a_pi.pdf
- Jadenu (deferasirox) [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation.; July 2019. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/jadenu.pdf>
- Lumizyme (alglucosidase alfa) [package insert]. Cambridge, MA: Genzyme Corporation; February 2020. <http://products.sanofi.us/Lumizyme/lumizyme.pdf>
- Nexplanon (etonogestrel) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; November 2019. https://www.merck.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf

Formatted: Font: 5 pt

Field Code Changed

Formatted: Font: 5 pt

Onpattro (patisiran) [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; February 2020.
<https://www.alnylam.com/wp-content/uploads/pdfs/ONPATTRO-Prescribing-Information.pdf>

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) [package insert]. Lenoir, NC: Greer Laboratories, Inc; October 2014.
<http://www.oralair.com/assets/pdf/ORALAIR%20Prescribing%20Information-Med%20Guide.pdf>

Proleukin (aldesleukin) [package insert]. San Diego, CA: Novartis Pharmaceuticals; August 2018.
https://www.proleukin.com/downloads/PR0011_Package%20Insert%20Clean.pdf

Prudoxin (doxepin hydrochloride) [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; June 2017.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ca53346b-8ab3-4722-98f6-cf272706d3fa&type=display>

Pulmozyme (dornase alfa) [package insert]. South San Francisco, CA: Genentech, Inc.; January 2018.
https://www.gene.com/download/pdf/pulmozyme_prescribing.pdf

Radicava (edaravone) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; August 2018.
<https://www.radicava.com/assets/dist/pdfs/radicava-prescribing-information.pdf>

Remodulin (treprostinil) [package insert]. Research Triangle Park, NC: United Therapeutics Corp; July 2018.
<https://www.remodulin.com/downloads/remodulin-prescribinginformation.pdf>

Rilutek (riluzole) [package insert]. Laval, Quebec: sanofi-aventis Canada Inc.; May 2010.
<http://products.sanofi.ca/en/rilutek.pdf>

Rybelsus (semaglutide) [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; January 2020. <https://www.novo-pi.com/rybelsus.pdf>

Samsca (tolvaptan) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; June 2018.
https://www.otsuka-us.com/media/static/Samsca-PI.pdf?_ga=2.25607163.771203294.1583949156-619624394.1582838717

Secuado (asenapine) [package insert]. Miami, FL: Noven Therapeutics, LLC; October 2019.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=685eaf44-5944-4f38-afba-0a4fc0b3462b&type=display>

Soliris (eculizumab) [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; June 2019.
https://alexion.com/Documents/Soliris_USPI.pdf

Sunosi (solriamfetol) [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; June 2019.
<https://pp.jazzpharma.com/pi/sunosi.en.USPI.pdf>

Sylatron (peginterferon alfa-2b) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; September 2015. https://www.merck.com/product/usa/pi_circulars/s/sylatron/sylatron_pi.pdf

Tegsedi (inotersen) [package insert]. Boston, MA: Akcea Therapeutics, Inc.; October 2019.
<https://tegsemi.com/prescribing-information.pdf>

Tiglutik (riluzole) [package insert]. Berwyn, PA: ITF Pharma, Inc.; December 2019.
https://tiglutikblob.blob.core.windows.net/tiglutik-web-assets/TIGLUTIK_PI_with_PEG_Updated_1_2020.pdf

Tylenol Extra Strength (acetaminophen) [package insert]. Ft. Washington, PA: McNeil Consumer; July 2019.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59773893-09a8-47a2-943a-e9ea9da4458a>

Tosymra (sumatriptan) [package insert]. Princeton, NJ: Promius Pharma, LLC; January 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210884s000lbl.pdf

Velettri (epoprostenol) [package insert]. San Francisco, CA: Actelion Pharmaceuticals US, Inc; December 2018.
https://www.velettri.com/pdf/velettri_full_prescribing_information_3rd_gen.pdf

Field Code Changed

Formatted: Font: 5 pt

Formatted: Font: 5 pt

Formatted: Font: 5 pt

Wakix (pitolisant) [package insert]. Plymouth Meeting, PA: Harmony Biosciences, LLC; November 2019.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e&type=display>

▲ Zonalon (doxepin hydrochloride) [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; June 2017.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5f302247-525e-4acc-852b-00eb1d79af4b&type=display>

Formatted: Font: 5 pt

Field Code Changed

Revision	Date
Modified Fycompa age, added sucralfate bypass diagnosis chart, modified wording in entire document for clarity	August 2019
Added diagnoses for Fabrazyme, Lumizyme, HIV Agents, expanded diagnosis code for malignant mast cell tumors, and added a new diagnosis for Soliris, removed allergen extracts Grastek® and Ragwitek®	November 2019
Removed First-Progesterone VGS®, added Tosymra® diagnosis requirement, quantity limit and reference, added some generics, made trademark and capitalization corrections	December 2019
Added POS information for Egrifta®/Egrifta SV™, Onpatro®, Radicava®, Rilutek®, Rybelsus®, Sunosi®, Tegsedi™, Tiglutik™, Wakix™; added references for Accutane®, Beyaz®, Fabrazyme®, Lumizyme®, Pulmozyme®, and Soliris®	March 2020
Added POS information for Cuprimine®, Depen®, Prudoxin®, Samsca®, Secuado® and Zonalon®	May 2020